drugset
drugset / Trial / NCT00654238

Phase II Trial of Sorafenib (Nexavar) in Patients With Advanced Thyroid Cancer

NCT00654238 ↗

Phase 2 Completed 59 enrolled University of Pennsylvania
NaSingle-groupOpen-labelTreatment

Summary

The goal of this study is to determine the activity of sorafenib in patients with advanced (metastatic or recurrent) thyroid cancer.

Timeline

Start
2006-02
Primary completion
2010-12
Completion
2011-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Sorafenib Small molecule 400 mg Oral

Indications

medullary thyroid gland carcinoma poorly differentiated thyroid gland carcinoma thyroid gland undifferentiated (anaplastic) carcinoma